



Current Projects:


- Live Oral Rotavirus Vaccine for Phase I Clinical Trials (PATH). [Exceeded titer spec by ~80%], contracted to make second lot.
- Manufactured cGMP Phase I Divalent VLP vaccine in BEVS.
- R&D contract to manufacture a lentiviral vector for preclinical tox. studies.
- Completed Phase I Dengue Vaccine for NIAID.
- Completed Phase I RSV Vaccine for NIAID.
- Completed Phase I r-RSV.
- Completed r-PIV3/RSV Vaccine NIAID.
- Completed 2nd r-Dengue Phase I Vaccine, NIAID.
- Contract for H1N1 influenza grown in eggs.
- Contract for RSV NS1 and RSV A1 Phase I Vaccines, NIAID.
- R&D contract to optimize cell culture and downstream processing of a Hepatitis A vaccine.




NIAID Experimental Vaccines Contract: MLS was awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID) Laboratory for production of 8 phase I clinical cGMP grade experimental vaccines. The contract requires production and safety testing of experimental non-Influenza, Influenza virus vaccines, and other vaccine-related products for use in humans. Specific activities include: 1) Manufacture of viruses shown to be promising candidates for use in vaccination of humans; 2) Preparation of wild type viruses needed for challenge studies to evaluate effectiveness of immunoprophylaxis or in pathogenesis studies; and 3) Manufacture and qualification of Master Cell Lines for production of these viruses or other uses as directed by NIAID.



Parvovirus B19 Vaccine: MLS has manufactured, and subsequently licensed, a recombinant Parvovirus B19 vaccine under a contract from the National Heart Lung and Blood Institute of the National Institutes of Health. The vaccine was manufactured according to cGMP in Meridian's fully qualified *Spodoptera Frugiperda* (Sf9) insect cell line and is now in Phase I/II safety/efficacy trials. The vaccine consists of two viral proteins (VP1 and VP2) in separate baculovirus vectors that are co-infected at the correct multiplicity of infections (MOI's) into Sf9 cells and that, upon expression; self assemble into immunogenic virus-like particles. MLS has a validated cGMP vialing line for this product of up to 2,500 vials.



RSV Clinical Challenge Stock: MLS has manufactured a cGMP Respiratory Syncytial Virus Clinical Challenge Stock (RSV-CS) from an original pediatric clinical isolate. The RSV-CS consists of an RSV high titer accession stock produced in characterized Vero cells infected with an RSV virus strain isolated from an original pediatric clinical sample. The RSV-CS enables precisely controlled clinical vaccine efficacy studies to demonstrate actual protection (vs. implied protection via neutralizing Ab response). For Anti-viral therapeutics, the RSV-CS also allows for precisely controlled clinical studies to show therapeutic efficacy in eliminating or mitigating the effects of the disease in patients who have developed a controlled RSV infection as compared to control.



For more information contact:

Daniel A. Shelly, Ph.D., MBA

5171 Wilfong Road • Memphis, TN USA 38134

800.327.6299 • 901.382.8716

E-mail: daniel.shelly@meridianlifescience.com

cGMP@meridianlifescience.com